...
首页> 外文期刊>BMC Cancer >Health services research of integrative oncology in palliative care of patients with advanced pancreatic cancer
【24h】

Health services research of integrative oncology in palliative care of patients with advanced pancreatic cancer

机译:综合肿瘤学在晚期胰腺癌患者姑息治疗中的卫生服务研究

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Background Pancreatic cancer has a dire prognosis and is associated with a high mortality. Palliative patients have special needs and often seek help in integrative oncological concepts (IO) that combine conventional and complementary therapies. Nevertheless there are few recommendations regarding IO in current cancer guidelines. The aims of this study were to report on implementation of IO in everyday palliative care and to analyze patient survival in advanced pancreatic cancer. Methods This multicenter observational study investigates the implementation of IO and length of survival of patients suffering from advanced pancreatic cancer (stage IV). We analyzed patient’s survival by employing multivariable proportional hazard models using different parametric distribution functions and compared patients receiving chemotherapy only, a combination of chemotherapy and Viscum album (VA) treatment, and VA treatment only. Results Records of 240 patients were analyzed. Complementary therapy showed high acceptance (93?%). Most frequent therapy was VA treatment (74?%) that was often administered concomitantly to chemotherapy (64?%). Both therapies had positive effects on patient survival as they had significant negative effects on the hazard in our log-normal model. A second analysis showed that patients with combined chemotherapy and VA therapy performed significantly better than patients receiving only chemotherapy (12.1 to 7.3?month). Patients receiving only VA therapy showed longer survival than those receiving neither chemotherapy nor VA therapy (5.4 to 2.5?months). Our data demonstrates that IO can be implemented in the everyday care of patients without disregarding conventional treatment. Patients combining VA with chemotherapy showed longest survival. Conclusions Our data demonstrate the importance and potential of health services research showing that IO treatment can be successfully implemented in the every-day care of patients suffering from advanced pancreatic cancer. Patients combining VA with chemotherapy showed longest survival. To address patients’ needs adequately, future cancer guidelines might increasingly include comments on complementary treatment options in addition to conventional therapies. Further studies should investigate the effect of complementary treatments on survival and quality of life in more detail.
机译:背景胰腺癌预后不良,死亡率高。姑息性患者有特殊需要,并且经常在结合传统疗法和补充疗法的综合肿瘤学概念(IO)中寻求帮助。但是,在当前的癌症指南中,很少有关于IO的建议。这项研究的目的是报告IO在日常姑息治疗中的实施情况,并分析晚期胰腺癌患者的生存率。方法这项多中心观察性研究调查了晚期胰腺癌(IV期)患者的IO实施和生存期。我们通过使用具有不同参数分布函数的多变量比例风险模型来分析患者的生存情况,并比较了仅接受化疗,接受化学疗法和Viscum Album(VA)联合治疗以及仅接受VA治疗的患者。结果分析240例患者的病历。辅助治疗显示出较高的接受率(93%)。最频繁的治疗是VA治疗(74%),通常与化疗同时进行(64 %%)。在我们的对数正态模型中,这两种疗法均对患者的生存产生积极影响,因为它们对危害具有显着的负面影响。第二项分析显示,化学疗法和VA疗法相结合的患者的表现明显好于仅接受化学疗法的患者(12.1至7.3个月)。仅接受VA疗法的患者比未接受化学疗法或VA疗法的患者显示更长的生存期(5.4至2.5个月)。我们的数据表明,可以在患者的日常护理中实施IO,而无需考虑常规治疗。 VA联合化疗的患者生存期最长。结论我们的数据表明了卫生服务研究的重要性和潜力,表明IO治疗可以成功地用于晚期胰腺癌患者的日常护理。 VA联合化疗的患者生存期最长。为了充分满足患者的需求,未来的癌症指南可能会越来越多地包括对常规疗法以外的补充治疗方案的评论。进一步的研究应更详细地研究补充治疗对生存和生活质量的影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号